Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,501–3,600 of 15,747
Hall, V. G., Al-Alahmadi, G., Solera, J. T., Marinelli, T. M., Cardinal, H., Prasad, G. V. R., Serres, S. A. D., Isaac, D., Mainra, R., Lamarche, C., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004178 · Cited by 32
Welbourne, E. N., Loveday, K. A., Nair, A., Nourafkan, E., Qu, J., Cook, K., Kis, Z., & Dickman, M. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1250833 · Cited by 37
Targeting the hallmarks of aging to improve influenza vaccine responses in older adults
Cadar, A. N., Martin, D. E., & Bartley, J. M. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00348-6 · Cited by 36
“Similarly, the Pfizer-BioNTech BNT162b2 vaccine showed between 94–96% efficacy in all individuals from 16 to over 65 years old [68].”
MethodFacile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA
Ahn, M., Song, J., & Hong, B. H. (2021) · Nanomaterials · doi:10.3390/nano11112816 · Cited by 31
Day, D., Grech, L., Nguyen, M., Bain, N. T., Kwok, A., Harris, S., Chau, H., Chan, B. A., Blennerhassett, R. C., Nott, L. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10060851 · Cited by 30
Garrett, M. E., Galloway, J. G., Wolf, C., Logue, J. K., Franko, N., Chu, H. Y., Matsen, F. A., IV, & Overbaugh, J. (2022) · eLife · doi:10.7554/elife.73490 · Cited by 38
“While these vaccines have been shown to effectively guard against infection, severe disease, and death related to SARS- CoV2 (Polack et al., 2020; Keehner et al., 2021; Amit et al., 2021; Angel et al., 2021; Thompson et al., 2021; Haas et al., 2021; Baden et al., 2021), less is known about how effective they will be a…”
BackgroundVaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
(2022) · doi:10.1101/2022.03.22.22272769 · Cited by 354
Interspecies Jumping of Bat Coronaviruses
Wong, A. C. P., Lau, S. K. P., & Woo, P. C. Y. (2021) · Viruses · doi:10.3390/v13112188 · Cited by 36
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 34
“SARS-CoV-2 vaccines protect against serious illness and death (20, 21).”
BackgroundTuan, J., Zapata, H. J., Critch‐Gilfillan, T., Ryall, L., Turcotte, B., Mutic, S., Andrews, L., Roh, M. E., Friedland, G., Barakat, L., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13188 · Cited by 30
Fernández-Ruiz, M., Almendro-Vázquez, P., Carretero, O., Ruiz-Merlo, T., Laguna-Goya, R., Juan, R. S., López‐Medrano, F., García‐Ríos, E., Más, V., Moreno-Batenero, M., et al. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001246 · Cited by 33
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 43
“Following the approval of the first LNP-siRNA drug (Adams et al. 2018; Akinc et al. 2019) and the COVID-19 LNP-mRNA vaccines (Baden et al. 2021; Polack et al. 2020), LNP-mRNA platform technology is currently being applied for various immunotherapy approaches, including treatment of infectious…”
de Boer, S. E., Berger, S. P., van Leer‐Buter, C., Kroesen, B., van Baarle, D., Sanders, J., & on behalf of the OPTIMIZE study group (2022) · Transplantation · doi:10.1097/tp.0000000000004177 · Cited by 31
Inhalable Dry Powders for Lung mRNA Delivery
Gordon, A. G. R., Li, B., Witten, J. J., Nguyen, H. Q., & Anderson, D. G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400509 · Cited by 38
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
Laurini, G. S., Montanaro, N., Broccoli, M., Bonaldo, G., & Motola, D. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.054 · Cited by 32
“The phase 3 trials of both COVID-19 mRNA vaccines noted an imbalance of cases of Bell’s palsy in the vaccine group compared with the placebo group [3,4].”
BackgroundFerrari, D., Clementi, N., Criscuolo, E., Ambrosi, A., Corea, F., Resta, C. D., Tomaiuolo, R., Mancini, N., Locatelli, M., Plebani, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111357 · Cited by 31
“Its administration protocol has been based on a double dose approach which proved to be effective in preventing 95% of COVID-19 cases [3,4].”
ResultSafety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
Polewska, K., Tylicki, P., Biedunkiewicz, B., Rucińska, A., Szydłowska, A., Kubanek, A., Rosenberg, I., Rodak, S., Ślizień, W., Renke, M., et al. (2021) · Medicina · doi:10.3390/medicina57070732 · Cited by 31
“A similar proportion of the dialyzed patients reported any solicited systemic reactions compared with control age and sex matched recipients, but much less than reported in the phase 3 trials [5].”
BackgroundMethodResultInfluentialDoherty, J., Fennessy, S., Stack, R., Morain, N. O., Cullen, G. J., Ryan, E. J., Gascun, C. F. D., & Doherty, G. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16590 · Cited by 31
Xu, Y., Zheng, Y., Ding, X., Wang, C., Hua, B., Hong, S., Huang, X., Lin, J., Zhang, P., & Chen, W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2219870 · Cited by 32
Structure and antigenicity of divergent Henipavirus fusion glycoproteins
Isaacs, A., Low, Y. S., Macauslane, K. L., Seitanidou, J., Pegg, C. L., Cheung, S. T. M., Liang, B., Scott, C. A. P., Landsberg, M. J., Schulz, B. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39278-8 · Cited by 31
Rahman, M. M., Zhou, N., & Huang, J. (2021) · Vaccines · doi:10.3390/vaccines9030244 · Cited by 36
Binici, B., Borah, A., Watts, J. A., McLoughlin, D. M., & Perrie, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124942 · Cited by 34
Yamamoto, S., Fukunaga, A., Tanaka, A., Takeuchi, J. S., Inoue, Y., Kimura, M., Maeda, K., Ueda, G., Mizoue, T., Ujiie, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.052 · Cited by 30
“According to the clinical trial of the BNT162b2 vaccine [1], one-fourth of the placebo recipients reported systemic symptoms (fatigue 23 % and headache 24 %) after the second dose, while only 0.”
Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China
Makhoul, M., Chemaitelly, H. S., Ayoub, H. H., Seedat, S., & Abu-Raddad, L. J. (2021) · Vaccines · doi:10.3390/vaccines9030223 · Cited by 29
Kirkham, A. M., Bailey, A. J.-M., Monaghan, M., Shorr, R., Lalu, M. M., Fergusson, D. A., & Allan, D. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac038 · Cited by 35
Cationic Lipid Pairs Enhance Liver-to-Lung Tropism of Lipid Nanoparticles for In Vivo mRNA Delivery
Zeng, G., He, Z., Yang, H., Gao, Z., Ge, X., Liu, L., Liu, Z., & Chen, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02415 · Cited by 33
SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728021 · Cited by 30
“include the spike protein as the vaccine antigen that elicits protective immunity (8, 9).”
BackgroundInfluentialAsano, M., Okada, H., Itoh, Y., Hirata, H., Ishikawa, K., Yoshida, E., Matsui, A., Kelly, E. J., Shoemaker, K., Olsson, U., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.030 · Cited by 34
Sealy, R. E., & Hurwitz, J. L. (2021) · Microorganisms · doi:10.3390/microorganisms9081643 · Cited by 33
Renn, M., Bartok, E., Zillinger, T., Hartmann, G., & Behrendt, R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107931 · Cited by 30
Structure and design of Langya virus glycoprotein antigens
Wang, Z., McCallum, M., Yan, L., Gibson, C. A., Sharkey, W., Park, Y.-J., Dang, H. V., Amaya, M., Person, A., Broder, C. C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314990121 · Cited by 32
“Prefusion - stabilization (2P) of coronavirus spike glycoproteins also led to the groundbreaking development of COVID - 19 vaccines in a record time (49, 67–69).”
Zhao, Y., Tian, Z., Wang, J., Cui, M., Cao, Z., Liu, P., Li, R., Cai, S., Hu, Y., Ma, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady6460 · Cited by 42
“Their utility was further demonstrated during the COVID-19 pandemic ( 2 , 3 ), enabling the rapid development and global deployment of mRNA vaccines, including Pfizer-BioNTech’s BNT162b2 ( 4 ) and Moderna’s mRNA-1273 ( 5 ).”
Sa, S., Lee, C. W., Shim, S. R., Yoo, H., Choi, J., Kim, J. H., Lee, K., Hong, M., & Han, H. W. (2022) · Vaccines · doi:10.3390/vaccines10020320 · Cited by 31
“Rare or serious outcomes associated with vaccines might not be identified in phase 3 trials because of limited sample sizes, restrictive inclusion criteria, limited follow-up durations, and trial participants who differ in meaningful ways from the population ultimately receiving the vaccines [4,5].”
BackgroundHertel, M., Schmidt‐Westhausen, A. M., Wendy, S., Heiland, M., Nahles, S., Preißner, R., & Preißner, S. (2022) · Vaccines · doi:10.3390/vaccines10030480 · Cited by 31
Towards the enzymatic synthesis of phosphorothioate containing LNA oligonucleotides
Flamme, M., Hanlon, S. P., Iding, H., Puentener, K., Sladojevich, F., & Hollenstein, M. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128242 · Cited by 31
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Sellner, J., & Rommer, P. S. (2021) · Vaccines · doi:10.3390/vaccines9020099 · Cited by 29
Zhan, H., Gao, H., Liu, Y., Zhang, X., Li, H., Li, X., Wang, L., Li, C., Li, B., Wang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28428 · Cited by 27
“The efficacy of SARS‐CoV‐2 vaccines reduces COVID‐19 severity and mortality rates by triggering robust humoral and cellular responses against the virus.(4,5) However, only a few clinical trials have focused on immunocompromised individuals because of their dysregulated host defenses.”
BackgroundLipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery
Sunoqrot, S., Gaber, S. A. A., Abujaber, R., Al-Majawleh, M., & Talhouni, S. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00843 · Cited by 35
Alkhalifah, M. I., Alsobki, H. E., Alwael, H. M., Fawaz, A. M. A., & Al‐Mezaine, H. S. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1986548 · Cited by 29
Delaying the second dose of covid-19 vaccines
Pimenta, D., Yates, C. A., Pagel, C., & Gurdasani, D. (2021) · BMJ · doi:10.1136/bmj.n710 · Cited by 37
Microsimulation based quantitative analysis of COVID-19 management strategies
Reguly, I. Z., Csercsik, D., Juhász, J., Tornai, K., Bujtár, Z., Horváth, G., Keömley-Horváth, B. M., Kós, T., Cserey, G., Iván, K., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009693 · Cited by 29
“reduced by 20% and 82% after 12- and 28-days post-vaccination [34], respectively.”
BackgroundSharma, T., Abohashrh, M., Baig, M. H., Dong, J.-J., Alam, M. M., Ahmad, I., & Irfan, S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.02.059 · Cited by 31
Predictors of mortality among long‐term care residents with SARS‐CoV ‐2 infection
Lee, D. S., Ma, S., Chu, A., Wang, C. X., Wang, X., Austin, P. C., McAlister, F. A., Kalmady, S. V., Kapral, M. K., Kaul, P., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17425 · Cited by 30
Ahmed, S. K., Mohamed, M. G., Essa, R. A., Dabou, E. A. R., Abdulqadir, S. O., & Omar, R. M. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101108 · Cited by 35
“Pain, erythema, swelling, fever, headache, and myalgia were reported as the most common systemic or local reactions [11].”
Hunjan, M. K., Roberts, C., Karim, S., et al. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14878 · Cited by 29
“In the BNT162b2 (Pfizer/ BionTech) mRNA vaccine Phase III study, no participants reported cutaneous adverse events aside from injection site reactions (1).”
BackgroundPhenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice
Cacicedo, M. L., Weinl, C., Frank, D., Limeres, M. J., Wirsching, S., Hilbert, K., Famian, M. A. P., Horscroft, N., Hennermann, J. B., Zepp, F., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.993298 · Cited by 34
Aptamers in neuro-oncology: An emerging therapeutic modality
Doherty, C. L., Wilbanks, B. A., Khatua, S., & Maher, L. J., III (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad156 · Cited by 34
Immunizing the imperfect immune system
Durkee-Shock, J., & Keller, M. (2022) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2022.06.009 · Cited by 20
Unexplained liver test elevations after SARS-CoV-2 vaccination
Guardiola, J., Lammert, C. S., Teal, E., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.014 · Cited by 29
“[1] Bril F, Al Diffalha S, Dean M, Fettig DM.”
BackgroundRäuber, S. J., Korsen, M., Huntemann, N., Rolfes, L., Müntefering, T., Dobelmann, V., Hermann, A. M., Kölsche, T., Lipinski, K. V. W., Schroeter, C. B., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328197 · Cited by 35
Implementation of covid-19 vaccination in the United Kingdom
Majeed, A., Pollock, K., Hodes, S., & Papaluca, M. (2022) · British medical journal · doi:10.1136/bmj-2022-070344 · Cited by 22
Urakawa, R., Isomura, E. T., Matsunaga, K., Kubota, K., & Ike, M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07175-y · Cited by 32
Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations
Santamarina-Fernández, R., Fuentes-Valverde, V., Silva-Rodríguez, A., García, P., Moscoso, M., & Bou, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052012 · Cited by 33
“Vaccination Against P. aeruginosa Historical successes, such as the eradication of smallpox [50] and the development of the SARS-Cov-2 vaccine [51,52] in record time, have Different strategies targeting VFs have been explored for more than 50 years, but no successful vaccine against this pathogen…”
Cortés, A., Casado, J. L., Longo, F., Domingo, J. J. S., Saavedra, C., Velasco, H., Martín, A., Chamorro, J., Rosero, D. I., Fernández-Abad, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.017 · Cited by 30
IHEANACHO, C. O., Eze, U. I. H., & Adida, E. A. (2021) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-021-00607-w · Cited by 31
Syversen, S. W., Jyssum, I., Tveter, A. T., Sexton, J., Christensen, I. E., Tran, T. T., Bjørlykke, K. H., Mjaaland, S., Warren, D. J., Kvien, T. K., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002417 · Cited by 30
Bettinger, J. A., Sadarangani, M., Serres, G. D., Valiquette, L., Vanderkooi, O. G., Kellner, J. D., Muller, M. P., Top, K. A., Isenor, J. E., McGeer, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051254 · Cited by 29
Goffe, L., Antonopoulou, V., Meyer, C., Graham, F., Tang, M. Y., Lecouturier, J., Grimani, A., Bambra, C. L., Kelly, M. P., & Sniehotta, F. F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002084 · Cited by 31
Berry, S. D., Goldfeld, K. S., McConeghy, K. W., Gifford, D. R., Davidson, H. E., Han, L., Syme, M. L., Gandhi, A. D., Mitchell, S. L., Harrison, J., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.8067 · Cited by 30
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesPreprint
Branche, A. R., Rouphael, N., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Anderson, E. J., et al. (2022) · medRxiv · doi:10.1101/2022.07.12.22277336 · Cited by 31
Haranaka, M., Baber, J., Ogama, Y., Yamaji, M., Aizawa, M., Kogawara, O., Scully, I. L., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27316-2 · Cited by 29
Self-citationCOVID-19 vaccine-associated cerebral venous thrombosis in GermanyPreprint
Schulz, J. B., Berlit, P., Diener, H., Gerloff, C. P., Greinacher, A., Klein, C., Petzold, G. C., Piccininni, M., Poli, S., Röhrig, R., et al. (2021) · medRxiv · doi:10.1101/2021.04.30.21256383 · Cited by 29
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 34
Mooij, P., García‐Arriaza, J., Pérez, P., Lázaro-Frías, A., Verstrepen, B. E., Böszörményi, K. P., Mortier, D., Fagrouch, Z. C., Kiemenyi-Kayere, G., Niphuis, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845887 · Cited by 32
Küçüksayan, E., Bozkurt, F., Yılmaz, M. T., Sırcan-Küçüksayan, A., Hanikoglu, A., & Özben, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-92447-x · Cited by 30
COVID-19 vaccine trials: The use of active controls and non-inferiority studies
Fleming, T. R., Krause, P. R., Nason, M., Longini, I. M., & Restrepo, A. M. H. (2021) · Clinical Trials · doi:10.1177/1740774520988244 · Cited by 28
Microneedle technology for potential SARS-CoV-2 vaccine delivery
McNamee, M., Wong, S., Guy, O. J., & Sharma, S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2209718 · Cited by 31
“The Pfizer vaccination is comprised of a modified nucleoside RNA vaccination coded against the SARS-CoV-2 spike (S) protein, encapsulated in a lipid nanoparticle [100].”
BackgroundMethodInfluentialLaing, E. D., Sterling, S. L., Richard, S. A., Epsi, N. J., Coggins, S. A., Samuels, E. C., Phogat, S., Yan, L., Moreno, N., Coles, C., et al. (2021) · medRxiv · doi:10.1101/2021.02.10.21251518 · Cited by 31
Wei, J., Stoesser, N., Matthews, P., et al. (2021) · medRxiv · doi:10.1101/2021.04.22.21255911 · Cited by 30
Terpos, E., Politou, M., Ntanasis‐Stathopoulos, I., Karalis, V. D., Merkouri, E., Fotiou, D., Gavriatopoulou, M., Malandrakis, P., Kastritis, E., Trougakos, I. P., et al. (2021) · Vaccines · doi:10.3390/vaccines9070712 · Cited by 28
“The BNT162b2 mRNA and the ChAdOx1 nCov-19 (AZD1222) adenovirus vector vaccines account for the majority of vaccinations around the world following encouraging clinical trial results [5,6].”
BackgroundInfluentialReuter, N., Chen, X., Kropff, B., Peter, A. S., Britt, W. J., Mach, M., Überla, K., & Thomas, M. (2023) · Viruses · doi:10.3390/v15071500 · Cited by 30
“Among the currently approved vaccines requiring de novo expression in the host are some that encode a diproline mutated spike (pre-lock), as for instance BNT162b2 (Pfizer, BioNTech) or mRNA-1273 (Moderna) [67,68].”
BackgroundHitchings, M., Lewnard, J., Dean, N., Ko, A. I., Ranzani, O., Andrews, J. R., & Cummings, D. A. T. (2021) · medRxiv · doi:10.1097/ede.0000000000001484 · Cited by 31
Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
Robertson, J. F. R., Sewell, H. F., & Stewart, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00455-4 · Cited by 26
Kolahchi, Z., Khanmirzaei, M., & Mowla, A. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120327 · Cited by 38
Vacunas frente a SARS-CoV-2 y piel
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.05.011 · Cited by 29
Lessons from Israel's COVID-19 Green Pass program
Kamin-Friedman, S., & Peled-Raz, M. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00496-4 · Cited by 36
“In spite of the uncertainty surrounding the long-term effectiveness of the mRNA COVID-19 vaccine as well as its effectiveness against variants, the implementation of the Green Pass scheme was based on research confirming that infection with COVID-19 induces an immune response [3], and that vaccines are (as of now) eff…”
MethodGuo, W., Deguise, J., Tian, Y., Huang, P. C.-E., Goru, R., Yang, Q., Peng, S., Zhang, L., Zhao, L., Xie, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870599 · Cited by 27
Acute Myocarditis after COVID-19 vaccination: A case report
Schmitt, P., Demoulin, R., Poyet, R., Capilla, E., Rohel, G., Pons, F., Jégo, C., Sidibe, S., Druelle, A., Brocq, F.-X., et al. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.10.003 · Cited by 31
“The most commonly reported side effects were typically tiredness, headaches, muscle pain, fever, and other severe adverse events were also noted as paroxysmal ventricular arrhythmia, hypertensive crisis, and right leg paresthesia [1].”
BackgroundMartellucci, C. A., Flacco, M. E., Soldato, G., Martino, G. D., Carota, R., Caponetti, A., & Manzoli, L. (2022) · Vaccines · doi:10.3390/vaccines10050662 · Cited by 34
COVID-19 vaccination and thyroiditis
Şendur, S. N., Oğuz, S. H., & Ünlütürk, U. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101759 · Cited by 31
Müller, M. K., Volzke, J., Subin, B., Müller, S. C., Sombetzki, M., Reisinger, E. C., & Müller‐Hilke, B. (2022) · BMC Medicine · doi:10.1186/s12916-022-02240-4 · Cited by 30
“An interactive web-based dashboard to track COVID-19 in real time.”
ResultInfluentialRapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
Jo, D. H., Minn, D., Lim, J., Lee, K.-D., Kang, Y. M., Choe, K. W., & Kim, K. N. (2021) · Vaccines · doi:10.3390/vaccines9101145 · Cited by 33
“The BNT162b2 vaccine is a novel type of vaccine that uses mRNA [3].”
BackgroundCOVID-19 vaccination in Israel
Muhsen, K., & Cohen, D. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.041 · Cited by 34
“While the BNT162b2 vaccine showed 95% efficacy against COVID-19 in a phase III trial [6], assessment of vaccine effectiveness in real life was needed.”
Fujigaki, H., Yamamoto, Y., Koseki, T., Banno, S., Ando, T., Ito, H., Fujita, T., Naruse, H., Hata, T., Moriyama, S., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01181-21 · Cited by 35
“83 One of the first approved COVID-19 vaccines, BNT162b2 (Pfizer/BioNTech), has 84 shown promising efficacy in clinical trials (7, 8).”
Suphanchaimat, R., Nittayasoot, N., Jiraphongsa, C., Thammawijaya, P., Bumrungwong, P., Tulyathan, A., Cheewaruangroj, N., Pittayawonganon, C., & Tharmaphornpilas, P. (2022) · Vaccines · doi:10.3390/vaccines10071080 · Cited by 36
“As a result, a combination of cellular and humoral immunity engenders higher and more prolonged immunity [32,33].”
BackgroundOcular Adverse Events after Coronavirus Disease 2019 mRNA Vaccination
Hashimoto, Y., Yamana, H., Iwagami, M., Ono, S., Takeuchi, Y., Michihata, N., Uemura, K., Yasunaga, H., Aihara, M., & Kaburaki, T. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.10.017 · Cited by 31
Kitonsa, J., Kamacooko, O., Bahemuka, U. M., Kibengo, F., Kakande, A., Wajja, A., Basajja, V., Lumala, A., Ssemwanga, E., Asaba, R., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251992 · Cited by 31
Hafiz, I., Illian, D. N., Meila, O., Utomo, A. R. H., Susilowati, A., Susetya, I. E., Desrita, D., Siregar, G. A., & Basyuni, M. (2022) · Vaccines · doi:10.3390/vaccines10010082 · Cited by 33
“mRNA-Based Vaccine Pfizer-BioNTech (BNT162b2) 113 95 (18,198 vaccinated, 18,325 Placebo) [60] 89.”
Gray, L. T., Raczy, M. M., Briquez, P. S., Marchell, T. M., Alpar, A. T., Wallace, R. P., Volpatti, L. R., Sasso, M. S., Cao, S., Nguyen, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121159 · Cited by 32
“developed by Pfizer-BioNTech [24] and Moderna [25], and one viral vector-based vaccine by Johnson&Johnson [20,26] were granted”
Kohler, P. P., Güsewell, S., Seneghini, M., Egger, T., Leal-Neto, O. B., Brucher, A., Lemmenmeier, E., Möller, J. C., Rieder, P., Ruetti, M., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02144-9 · Cited by 27
Retinal Hemorrhage after SARS-CoV-2 Vaccination
Park, H. S., Byun, Y., Byeon, S. H., Kim, S. S., Kim, Y. J., & Lee, C. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235705 · Cited by 30
“Some vaccines are DNA or mRNA vaccines [2,3], as opposed to conventional live-attenuated or viral-vectored vaccines, but were nevertheless approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) exceptionally quickly, given the grave global situation.”
BackgroundБарчук, А. А., Cherkashin, M., Bulina, A., Berezina, N., Rakova, T., Kuplevatskaya, D., Stanevich, O. V., Skougarevskiy, D. A., & Okhotin, A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02509-8 · Cited by 30
“Even though the results from clinical trials of Gam-COVID-Vac [1, 2] suggested safety and efficacy similar to other COVID-19 vaccines used in population-based programmes across the globe [3, 4], this finding was met with scepticism and criticism [5–9].”
ResultSchmidt, T., Klemis, V., Schub, D., et al. (2021) · medRxiv · doi:10.1101/2021.06.13.21258859 · Cited by 29
Patel, D. R., Field, C. J., Septer, K. M., Sim, D. G., Jones, M. J., Heinly, T. A., Vanderford, T. H., McGraw, E. A., & Sutton, T. C. (2021) · Journal of Virology · doi:10.1128/jvi.02232-20 · Cited by 33
Unraveling Attributes of COVID-19 Vaccine Hesitancy and Uptake in the U.S.: A Large Nationwide StudyPreprint
McCabe, S., Hammershaimb, E. A., Cheng, D. R., et al. (2021) · medRxiv · doi:10.1101/2021.04.05.21254918 · Cited by 29
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen, J., Fan, J., Zhao, Y., Jiang, D., Niu, Z., Zhang, Z., & Cao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159326 · Cited by 44
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.